Cetera Investment Advisers’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $210M | Buy |
965,429
+15,857
| +2% | +$3.52M | 0.22% | 86 |
|
|
2025
Q4 | $217M | Buy |
949,572
+24,222
| +3% | +$5.52M | 0.24% | 79 |
|
|
2025
Q3 | $214M | Buy |
925,350
+244,039
| +36% | +$49.7M | 0.25% | 77 |
|
|
2025
Q2 | $126M | Buy |
681,311
+28,786
| +4% | +$5.35M | 0.21% | 90 |
|
|
2025
Q1 | $137M | Buy |
652,525
+28,846
| +5% | +$5.61M | 0.26% | 74 |
|
|
2024
Q4 | $111M | Buy |
623,679
+10,254
| +2% | +$1.89M | 0.23% | 81 |
|
|
2024
Q3 | $121M | Buy |
613,425
+3,202
| +0.5% | +$598K | 0.27% | 74 |
|
|
2024
Q2 | $105M | Buy |
610,223
+1,999
| +0.3% | +$331K | 0.24% | 82 |
|
|
2024
Q1 | $111M | Buy |
608,224
+418,540
| +221% | +$72.1M | 0.26% | 77 |
|
|
2023
Q4 | $29.4M | Buy |
189,684
+1,876
| +1% | +$274K | 0.24% | 74 |
|
|
2023
Q3 | $28M | Buy |
187,808
+2,695
| +1% | +$396K | 0.24% | 79 |
|
|
2023
Q2 | $24.9M | Sell |
185,113
-10,548
| -5% | -$1.55M | 0.21% | 87 |
|
|
2023
Q1 | $31.2M | Sell |
195,661
-3,210
| -2% | -$491K | 0.27% | 66 |
|
|
2022
Q4 | $32.1M | Buy |
198,871
+67,691
| +52% | +$10.4M | 0.3% | 62 |
|
|
2022
Q3 | $17.6M | Sell |
131,180
-20,752
| -14% | -$2.98M | 0.35% | 54 |
|
|
2022
Q2 | $23.3M | Sell |
151,932
-18,123
| -11% | -$2.77M | 0.37% | 45 |
|
|
2022
Q1 | $27.6M | Buy |
170,055
+3,195
| +2% | +$464K | 0.4% | 44 |
|
|
2021
Q4 | $22.6M | Buy |
166,860
+14,200
| +9% | +$1.68M | 0.32% | 53 |
|
|
2021
Q3 | $16.5M | Sell |
152,660
-376
| -0.2% | -$43K | 0.26% | 79 |
|
|
2021
Q2 | $17.2M | Buy |
153,036
+25,794
| +20% | +$2.91M | 0.28% | 74 |
|
|
2021
Q1 | $13.8M | Sell |
127,242
-13,713
| -10% | -$1.47M | 0.27% | 78 |
|
|
2020
Q4 | $15.1M | Buy |
140,955
+112,087
| +388% | +$10.8M | 0.3% | 70 |
|
|
2020
Q3 | $2.53M | Buy |
28,868
+2,920
| +11% | +$275K | 0.21% | 121 |
|
|
2020
Q2 | $2.55M | Buy |
25,948
+5,464
| +27% | +$481K | 0.24% | 109 |
|
|
2020
Q1 | $1.56M | Sell |
20,484
-3,727
| -15% | -$317K | 0.19% | 136 |
|
|
2019
Q4 | $2.15M | Sell |
24,211
-1,312
| -5% | -$109K | 0.22% | 121 |
|
|
2019
Q3 | $1.94M | Sell |
25,523
-111
| -0.4% | -$7.61K | 0.24% | 114 |
|
|
2019
Q2 | $1.86M | Sell |
25,634
-619
| -2% | -$48.7K | 0.24% | 110 |
|
|
2019
Q1 | $2.11M | Buy |
26,253
+1,385
| +6% | +$113K | 0.3% | 92 |
|
|
2018
Q4 | $2.3M | Buy |
24,868
+279
| +1% | +$24.5K | 0.37% | 75 |
|
|
2018
Q3 | $2.33M | Sell |
24,589
-5,751
| -19% | -$545K | 0.33% | 80 |
|
|
2018
Q2 | $2.81M | Buy |
30,340
+477
| +2% | +$46.6K | 0.49% | 50 |
|
|
2018
Q1 | $2.83M | Sell |
29,863
-3,524
| -11% | -$387K | 0.53% | 49 |
|
|
2017
Q4 | $3.23M | Buy |
33,387
+547
| +2% | +$51.6K | 0.59% | 39 |
|
|
2017
Q3 | $2.91M | Sell |
32,840
-613
| -2% | -$46.7K | 0.64% | 35 |
|
|
2017
Q2 | $2.43M | Buy |
33,453
+5,062
| +18% | +$340K | 0.59% | 43 |
|
|
2017
Q1 | $1.85M | Buy |
28,391
+6,873
| +32% | +$432K | 0.51% | 52 |
|
|
2016
Q4 | $1.34M | Buy |
21,518
+4,281
| +25% | +$261K | 0.45% | 63 |
|
|
2016
Q3 | $1.09M | Sell |
17,237
-6,367
| -27% | -$412K | 0.47% | 57 |
|
|
2016
Q2 | $1.46M | Sell |
23,604
-52
| -0.2% | -$3.17K | 0.57% | 45 |
|
|
2016
Q1 | $1.35M | Buy |
23,656
+1,052
| +5% | +$58.6K | 0.59% | 41 |
|
|
2015
Q4 | $1.34M | Buy |
+22,604
| New | +$1.3M | 0.61% | 45 |
|
Other funds holding ABBV
VCM
VPM
Cetera Investment Advisers's ABBV Position: Q1 2026 in Review
Cetera Investment Advisers increased its AbbVie (ABBV) stake by 1.7% in Q1 2026, buying an estimated $3.52M and bringing the position to 965,429 shares worth $210M. The position accounts for 0.22% of the portfolio, ranked #86.
Cetera Investment Advisers first reported a position in ABBV in Q4 2015 and has held it in 42 quarters since. The position peaked at $217M in Q4 2025. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Cetera Investment Advisers held 965,429 shares of AbbVie worth $210M as of Q1 2026.
- Cetera Investment Advisers bought 15,857 AbbVie shares in Q1 2026, an estimated $3.52M.
- AbbVie made up 0.22% of Cetera Investment Advisers's portfolio in Q1 2026, its #86 holding.
- Cetera Investment Advisers first reported a position in AbbVie in Q4 2015 and has held it in 42 quarters since.
- Cetera Investment Advisers's AbbVie position peaked at $217M in Q4 2025.
- 4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Cetera Investment Advisers's 13F filing for Q1 2026, filed 13 May 2026.